As described above, mutations in the EGFR gene downstream signaling pathways (RAS/PIK3CA/PTEN) have recently been shown to be associated with the clinical outcome of EGFR-TKI treatment in patients with NSCLC; therefore, we evaluated and focused on these mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.